The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 20, 2024

Filed:

Mar. 14, 2017
Applicant:

Repertoire Genesis Incorporation, Ibaraki, JP;

Inventors:

Tadasu Shini, Shizuoka, JP;

Ryuji Suzuki, Tokyo, JP;

Assignee:
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C12Q 1/6881 (2018.01); C07K 7/04 (2006.01); G01N 33/574 (2006.01); G01N 33/68 (2006.01); G16B 5/00 (2019.01); G16B 5/20 (2019.01); G16B 15/00 (2019.01); G16B 15/30 (2019.01); G16B 20/00 (2019.01); G16B 20/20 (2019.01); G16B 20/30 (2019.01); G16B 25/10 (2019.01); G16B 30/00 (2019.01); G16B 30/10 (2019.01); G16B 40/00 (2019.01); G16B 45/00 (2019.01); G16B 50/10 (2019.01); G16B 50/20 (2019.01);
U.S. Cl.
CPC ...
C12Q 1/6881 (2013.01); C07K 7/04 (2013.01); G01N 33/574 (2013.01); G01N 33/6878 (2013.01); G16B 5/00 (2019.02); G16B 5/20 (2019.02); G16B 15/00 (2019.02); G16B 15/30 (2019.02); G16B 20/00 (2019.02); G16B 20/20 (2019.02); G16B 20/30 (2019.02); G16B 25/10 (2019.02); G16B 30/00 (2019.02); G16B 30/10 (2019.02); G16B 40/00 (2019.02); G16B 45/00 (2019.02); G16B 50/10 (2019.02); G16B 50/20 (2019.02); C12Q 2600/156 (2013.01);
Abstract

The present invention provides a method for producing a peptide for the treatment (in particular, immunotherapy), monitoring, or diagnosis of a disease in a subject. This method is achieved by obtaining information pertaining to a genome read, for example an exome read, of the subject and a mutation thereof, and, as necessary, information regarding the RNA sequence of the subject and information regarding the MHC type of the subject, analyzing an epitope related to the mutation on the basis of the information pertaining to the genome read (for example, the exome read) and the mutation, arbitrary information from the RNA sequence, the MHC type information, and information regarding the disease, and producing a peptide, as necessary, on the basis of information regarding the epitope.


Find Patent Forward Citations

Loading…